Fibroblast growth factor 2 mediates isoproterenol-induced cardiac hypertrophy through activation of the extracellular regulated kinase

Molecular and Cellular Pharmacology

Volumn 2, Issue 4, 2010, Pages 143-154

  House, Stacey L ^a,b   House, Brian E ^b   Glascock, Betty ^c   Kimball, Thomas ^c   Nusayr, Eyad ^d   Schultz, Jo El J ^b   Doetschman, Thomas ^b,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

Basic FGF; Cardiac hypertrophy; ERK; Extracellular regulated kinase; FGF2; Fibroblast growth factor; Isoproterenol; MAPK; Mitogen associated protein kinase

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; FIBROBLAST GROWTH FACTOR 2; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC STIMULATION; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME INHIBITION; GENE ACTIVATION; GENE OVEREXPRESSION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; MOUSE; MUSCLE CELL; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSGENE;

MUS; MUS MUSCULUS;

EID: 78049438071     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.10.20     Document Type: Article

References (54)

1. Parker TG, Packer SE, Schneider MD. Peptide growth factors can provoke fetal contractile protein gene expression in rat cardiac myocytes. J Clin Invest 1990;85:507-14.
2. Lompre AM, Mercadier JJ, Schwartz K. Changes in gene expression during cardiac growth. Int Rev Cytol 1991;124:137-86.
3. Izumo S, Lompre AM, Matsuoka R, et al. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest 1987;79:970-7.
4. Schwartz K, de la Bastie D., Bouveret P, Oliviero P, Alonso S, Buckingham M. Alpha-skeletal muscle actin mRNA's accumulate in hypertrophied adult rat hearts. Circ Res 1986;59:551-5.
5. Schoenfeld JR, Vasser M, Jhurani P, et al. Distinct molecular phenotypes in murine cardiac muscle development, growth, and hypertrophy. J Mol Cell Cardiol 1998;30:2269-80.
6. Kaye D, Pimental D, Prasad S, et al. Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro. J Clin Invest 1996;97:281-91.
7. Clarke MS, Caldwell RW, Chiao H, Miyake K, McNeil PL. Contraction-induced cell wounding and release of fibroblast growth factor in heart. Circulation Research 1995;76:927-34.
8. Schultz JJ, Witt SA, Nieman ML, et al. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest 1999;104:709-19.
9. Pellieux C, Foletti A, Peduto G, et al. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest 2001;108:1843-51.
10. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165-97.
11. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
12. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
13. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-32.
14. Cuenda A, Rouse J, Doza YN, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995;364:229-33.
15. House SL, Bolte C, Zhou M, et al. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation 2003;108:3140-8.
16. Zhou M, Sutliff RL, Paul RJ, et al. Fibroblast growth factor 2 control of vascular tone. Nat Med 1998;4:201-7.
17. Meij JT, Sheikh F, Jimenez SK, Nickerson PW, Kardami E, Cattini PA. Exacerbation of myocardial injury in transgenic mice overexpressing FGF-2 is T cell dependent. Am J Physiol Heart Circ Physiol 2002;282:H547-H555.
18. Molkentin JD, Dorn IG. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 2001;63:391-426.:391-426.
19. Osadchii OE. Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects. Heart Fail Rev 2007;12:66-86.
20. Yamashita H, Sato N, Kizaki T, et al. Norepinephrine stimulates the expression of fibroblast growth factor 2 in rat brown adipocyte primary culture. Cell Growth Differ 1995;6:1457-62.
21. DiMario J, Buffinger N, Yamada S, Strohman RC. Fibroblast growth factor in the extracellular matrix of dystrophic (mdx) mouse muscle. Science 1989;244:688-90.
22. Safran A, Avivi A, Orr-Urtereger A, et al. The murine flg gene encodes a receptor for fibroblast growth factor. Oncogene 1990;5:635-43.
23. Kouhara H, Hadari YR, Spivak-Kroizman T, et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 1997;89:693-702.
24. Wang JK, Xu H, Li HC, Goldfarb M. Broadly expressed SNT-like proteins link FGF receptor stimulation to activators of Ras. Oncogene 1996;13:721-9.
25. Liu L, Pasumarthi KB, Padua RR, et al. Adult cardiomyocytes express functional high-affinity receptors for basic fibroblast growth factor. American Journal of Physiology 1995;268:Pt 2):H1927-38.
26. House SL, Branch K, Newman G, Doetschman T, Schultz JJ. Cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2 is mediated by the MAPK cascade. Am J Physiol Heart Circ Physiol 2005;289:H2167-H2175.
27. Padua RR, Merle PL, Doble BW, et al. FGF-2-induced negative inotropism and cardioprotection are inhibited by chelerythrine: involvement of sarcolemmal calcium-independent protein kinase C. J Mol Cell Cardiol 1998;30:2695-709.
28. Rapacciuolo A, Esposito G, Prasad SV, Rockman HA. G protein-coupled receptor signalling in in vivo cardiac overload. Acta Physiol Scand 2001;173:51-7.
29. Takeishi Y, Huang Q, Abe J, Glassman M, et al. Src and multiple MAP kinase activation in cardiac hypertrophy and congestive heart failure under chronic pressure-overload: comparison with acute mechanical stretch. J Mol Cell Cardiol 2001;33:1637-48.
30. Lazou A, Sugden PH, Clerk A. Activation of mitogen-activated protein kinases (p38-MAPKs, SAPKs/JNKs and ERKs) by the G-protein-coupled receptor agonist phenylephrine in the perfused rat heart. Biochem J 1998;332:459-65.
31. Faulx MD, Ernsberger P, Vatner D, et al. Strain-dependent beta-adrenergic receptor function influences myocardial responses to isoproterenol stimulation in mice. Am J Physiol Heart Circ Physiol 2005;289:H30-H36.
32. Berthonneche C, Peter B, Schupfer F, et al. Cardiovascular response to beta-adrenergic blockade or activation in 23 inbred mouse strains. PLoS One 2009;4:e6610.
33. Behr TM, Nerurkar SS, Nelson AH, et al. Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 2001; 104:1292-8.
34. Yue TL, Gu JL, Wang C, et al. Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem 2000;275:37895-901.
35. Bueno OF, De Windt LJ, Lim HW, et al. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res 2001;88:88-96.
36. Bueno OF, De Windt LJ, Tymitz KM, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000;19:6341-50.
37. Gum RJ, McLaughlin MM, Kumar S, et al. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J Biol Chem 1998;273:15605-10.
38. Ge B, Gram H, Di Padova F, et al. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science 2002;295:1291-4.
39. Tanno M, Gorog DA, Bellahcene M, Cao X, Quinlan RA, Marber MS. Tumor necrosis factor-induced protection of the murine heart is independent of p38-MAPK activation. J Mol Cell Cardiol 2003;35:1523-7.
40. Maulik N, Yoshida T, Zu YL, Sato M, Banerjee A, Das DK. Ischemic preconditioning triggers tyrosine kinase signaling: a potential role for MAPKAP kinase 2. Am J Physiol 1998;275:H1857-H1864.
41. Reszka AA, Seger R, Diltz CD, Krebs EG, Fischer EH. Association of mitogen-activated protein kinase with the microtubule cytoskeleton. Proc Natl Acad Sci U S A 1995;92:8881-5.
42. Iijima Y, Laser M, Shiraishi H, et al. c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J Biol Chem 2002;277:23065-75.
43. Wang L, Gout I, Proud CG. Cross-talk between the ERK and p70 S6 kinase (S6K) signaling pathways. MEK-dependent activation of S6K2 in cardiomyocytes. J Biol Chem 2001;276:32670-7.
44. Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 1999;11:211-8.
45. Liang Q, De Windt LJ, Witt SA, Kimball TR, Markham BE, Molkentin JD. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem 2001;276:30245-53.
46. Morimoto T, Hasegawa K, Kaburagi S, et al. Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. J Biol Chem 2000;275:13721-6.
47. Molkentin JD. The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem 2000;275:38949-52.
48. Eriksson AE, Cousens LS, Weaver LH, Matthews BW. Three-dimensional structure of human basic fibroblast growth factor. Proc Natl Acad Sci U S A 1991;88:3441-5.
49. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA2 is phosphorylated and activated by MAP kinase. Cell 1993;72:269-78.
50. Frodin M, Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 1999;151:65-77.
51. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 1997;18:26-45.
52. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2:REVIEWS3005.
53. House SL, Melhorn SJ, Newman G, Doetschman T, Schultz JJ. The protein kinase C pathway mediates cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2. Am J Physiol Heart Circ Physiol 2007;293:H354-H365.
54. Carpenter G, Porter D, House SL, Liao S, Newman G, Schultz JJ. Inducible nitric oxide synthase (iNOS), not neuronal NOS (nNOS) in cardioprotection by fibroblast growth factor-2 (FGF-2). J Mol Cell Cardiol 2007;42:S187.